Originators, brand and portfolio teams
Lifecycle, licensing and portfolio decisions turn on dates that sit in 32 national registers, and on what competitors have filed. MPA keeps that picture current, product by product and country by country, with the records to back it.
The questions you face
Where exactly does our protection end in each market, counting SPCs, paediatric extensions and data exclusivity, and where is it under challenge?
Which generics and biosimilars have licences or authorisations in hand, and in which countries?
For an in-licensing or acquisition candidate, what is the real exclusivity position behind the headline date?
How is demand and published pricing moving for our products and the ones we compete with?
How MPA helps
The official data, kept current, with the experience to read it. We have done this since 1973.
Your position, and theirs
Patents, SPCs and first authorisation dates for products across Europe, with status as the registers state it, for your portfolio and the products around it.
Who has been granted what
UK and European licences and parallel import licences with holders, so competitor entry and parallel flows are visible early.
Commercial reading included
Interpretation of what a filing, a ruling or a register change means for a product, from people who have followed these markets since 1973.
“An invaluable component of our marketing and corporate decision-making strategic planning processes.”
What to read first
All resources- ExplainersPatent cover, data exclusivity and market protectionPatents are only one of the barriers between a generic and the market. Regulatory data protection runs on its own clock from the first EU authorisation and can block generics when no patent does. What the 8+2+1 rule means, how the UK and EU now differ, and what the 2026 reform changes.
- Regulatory changesThe EU's new data and market exclusivity rulesThe agreed EU pharmaceutical package keeps eight years of data protection but cuts baseline market protection from two years to one, with one-year extensions that have to be earned and an eleven-year cap. Adopted by the Council in September 2026, awaiting Parliament's vote, and applying only to products filed from late 2028. What changes, what does not, and what it means for generic entry dates.
- ExplainersPaediatric extensionsAn extra six months on an SPC, granted to originators that complete an agreed paediatric investigation plan. Small on paper, large in revenue, and a frequent surprise for generics and parallel traders who planned on the SPC date. How it works and where to look.
- ExplainersSecond medical use patents and skinny labelsWhen the compound is free but one of its uses is still patented, a generic launches with that use cut out of its label. What a second-medical-use patent claims, how the carve-out works, why the UK pregabalin litigation turned on how a product is presented rather than what it is used for, how Germany and the Netherlands differ, and what it means for prescribing, dispensing and sourcing.
- ExplainersThe Unified Patent Court and the unitary patentSince June 2023 one court can revoke, or enforce, a European patent across most of the EU in a single decision. Which countries are in, what the opt-out means, why there is still no unitary SPC, and how to read a product's position in a Europe that is now two systems.
- ExplainersWhy published patent-expiry lists disagree, and how to check a date yourselfSearch for any blockbuster's European patent expiry and you will find three different years. The lists are not all wrong; they are measuring different things. The six reasons they diverge, and a short procedure for getting the date that applies to your product and country.
See MPA Search in action
A free online demonstration with our team, with time for your questions.